Crohn’s Disease PROFILE Trial Protocol Published
PredictImmune is pleased to announce the e-publication of the PRedicting Outcomes For Crohn’s dIsease using a moLecular biomarker (PROFILE) trial protocol in the BMJ.
Cambridge, UK, 06 December 2018: The PROFILE trial is the first biomarker-stratified study in Crohn’s disease. The BMJ Open publication describes that the trial seeks to demonstrate that the combination of stratifying patients based on their risk of experiencing a frequently relapsing disease course, in addition with top-down or step-up treatment options, can result in improved outcomes by using a more personalised therapy for each patient.
PROFILE opened for recruitment in December 2017. It hopes to enrol 400 newly diagnosed patients (within 3 months of diagnosis) with active Crohn’s disease. The study already has 38 sites across the United Kingdom with 58 randomised patients. The trial is still open for recruitment and continues to accept new sites.
“The clear goal of this study is to dramatically reduce the impact of Crohn’s disease on people’s lives”
Helen Terry, Director of Policy, Public Affairs and Research at Crohn’s and Colitis UK, said, ‘We are delighted to see the launch of the PROFILE study in patients with newly diagnosed Crohn’s disease. A lot has been said about personalised medicine, but this study promises to make it a reality and to have a major impact on how Crohn’s disease is treated in the future. The clear goal of this study is to dramatically reduce the impact of Crohn’s disease on people’s lives, both in terms of symptoms and quality of life. We at Crohn’s and Colitis UK wish the investigators and participants every success.’
To get involved, become a PROFILE site, or for more information, go to the trial website: www.crohnsprofiletrial.com